Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
J Hematol Oncol. 2021.
PMID: 34001183
Free PMC article.
Clinical Trial.